Merck KGaA, a global science and technology company, announced on October 30, the signing of a Memorandum of Understanding with Samsung BioLogics for a strategic alliance on biopharmaceutical manufacturing and biologics process development.
The alliance aims to accelerate process development and clinical material production for small biotech start-ups focusing on novel drug development. Under the agreement, Merck will provide process development and support technical training, in addition to its Mobius® single-use to Samsung BioLogics.
“Our purpose is to solve the toughest problems in the industry by collaborating with the global scientific community,” said Udit Batra, Member of the Merck Executive Board and CEO, Life Science. “Our alliance with Samsung BioLogics is the ideal collaboration to advance development of potentially life-saving medicines.”
Merck has been the key solution provider for Samsung BioLogics’ 30KL facility and 152KL facility in Korea, and has trained Samsung BioLogics team on building a robust biologics development process.
The alliance is an extension of a MoU signed in 2014 intended to encompass a long-term supply agreement in which Merck provides raw materials for biopharmaceutical manufacturing.